Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass (Cerebrale en cardiale protectie met allopurinol bij neonaten met een ernstige aangeboren hartafwijking die een hartoperatie met behulp van hartlongmachine ondergaan).

Trial Profile

CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass (Cerebrale en cardiale protectie met allopurinol bij neonaten met een ernstige aangeboren hartafwijking die een hartoperatie met behulp van hartlongmachine ondergaan).

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allopurinol (Primary)
  • Indications Congenital heart defects
  • Focus Therapeutic Use
  • Acronyms CRUCIAL
  • Most Recent Events

    • 04 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top